Table 1. Baseline patient... | American Society of Hematology

Table 1.

Baseline patient characteristics

Patient characteristics (n = 67)	N	%
Median age (IQR; range), y	58 (51-67; 21-77)	—
Male sex	39	58.2
Underlying malignancy
Acute myelogenous leukemia	15	22.4
Non-Hodgkin lymphoma	15	22.4
Myelodysplastic syndrome	12	17.9
Other leukemia	10	14.9
Multiple myeloma	9	13.4
Other diseases*	6	9.0
Myeloablative conditioning among all patients	30	44.8
Autologous HCT	13	19.4
Type of allogeneic HCT (n = 54)
Matched-related donor	15	27.8
Matched-unrelated donor	32	59.3
Mismatched donor	7	13.0
Active GVHD (among allogeneic HCT recipients)	32	59.3
Immunosuppression† (among allogeneic HCT recipients, n = 54)	43	79.6
Glucocorticoids	27	50.0
Tacrolimus	31	57.4
Sirolimus	12	22.2

Patient characteristics (n = 67)	N	%
Median age (IQR; range), y	58 (51-67; 21-77)	—
Male sex	39	58.2
Underlying malignancy
Acute myelogenous leukemia	15	22.4
Non-Hodgkin lymphoma	15	22.4
Myelodysplastic syndrome	12	17.9
Other leukemia	10	14.9
Multiple myeloma	9	13.4
Other diseases*	6	9.0
Myeloablative conditioning among all patients	30	44.8
Autologous HCT	13	19.4
Type of allogeneic HCT (n = 54)
Matched-related donor	15	27.8
Matched-unrelated donor	32	59.3
Mismatched donor	7	13.0
Active GVHD (among allogeneic HCT recipients)	32	59.3
Immunosuppression† (among allogeneic HCT recipients, n = 54)	43	79.6
Glucocorticoids	27	50.0
Tacrolimus	31	57.4
Sirolimus	12	22.2

IQR, interquartile range.

Other diseases included myelofibrosis (n = 3), aplastic anemia (n = 2), and Langerhans cell histiocytosis.

Systemic immunosuppression included prednisone, tacrolimus, sirolimus, and mycophenolate mofetil.